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Tertiary lymphoid organs (TLOs) are induced postnatally in non-lymphoid tissues such 
as those affected by chronic infections, autoimmune diseases, and chronic allograft 
rejection, and also in cancer tissues. TLOs are thought to provide important lymphocytic 
functional environments for both cellular and humoral immunity, similar to lymph nodes 
or Peyer’s patches. TLOs have a structure similar to that of lymph nodes or Peyer’s 
patches, including T cell zones, B cell follicles, and high endothelial venules (HEV) with-
out encapsulation. Here, we review recent advances in our knowledge of TLOs in human 
solid cancers, including their location, structure, methods of evaluation, and clinicopath-
ological impact. We also discuss the formation and/or maintenance of TLOs in cancer 
tissues in association with the tumor immune microenvironment, cancer invasion, and 
the tissue structure of the cancer stroma.
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iNTRODUCTiON
Cancer tissue is composed of cancer cells and a stroma (alternatively referred to as the cancer 
microenvironment or tumor microenvironment), and cancer cells themselves, the cancer stroma, 
and their interaction can determine the biological behavior of the cancer (1). The cancer stroma is 
composed of vessels, fibroblasts, immune cells, and an extracellular matrix, making cancer tissue 
analogous to a form of organ. The host immune system is one of the leading players in the tumor 
microenvironment (1), and plays a critical role in tumor surveillance (2–4). The host antitumor 
immune reaction differs according to tumor type, tumor developmental stage, and the tissue from 
which the tumor develops. For example, colon cancers with many gene mutations such as those with 
microsatellite instability (MSI) tend to be immunogenic with a higher number of tumor-infiltrating 
lymphocytes (TILs) (5, 6), and many respond to immunotherapy with immune checkpoint inhibi-
tors, although many patients with colon cancer do not achieve the same degree of effect with any 
given immunotherapy due to non-immunogenicity of the tumor (7).
Tumor-infiltrating immune cells often represent the host immune reaction. The presence of 
high numbers of TILs has been found to be a major predictor of favorable clinical outcome in 
many types of solid cancer, such as colorectal, lung, ovarian, and pancreatic cancers (8, 9). Cells of 
myeloid lineage, such as macrophages, granulocytes, and mast cells, also infiltrate tumor tissues, 
especially macrophages, which are usually the most abundant cells infiltrating tumor tissues, and 
these myeloid cells exert many biological effects in cancer (10–16). These tumor-infiltrating myeloid 
cells have also been shown to be prognostically significant (9, 12). The tumor immune microenvi-
ronment shows a drastic change during the natural history of tumor development and progression, 
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i.e., from an immune reaction to immune tolerance during the 
progression of multi-step carcinogenesis (17–19). Meanwhile, 
inflammatory responses affect tumor development at different 
stages, including initiation, promotion, malignant conversion, 
invasion, and metastasis (20). Tumor-infiltrating immune cells 
engage in extensive and dynamic cross-talk with cancer cells, and 
some of the molecular events that mediate this dialog have been 
revealed (20). Accumulated evidence suggests that even the same 
types or subsets of tumor-infiltrating immune cells sometimes 
have different and opposite effects on patient outcome (8, 21).
The central mechanism involved in cellular immune reactions 
begins when immature dendritic cells (DCs) take up foreign 
antigens and then migrate to regional lymph nodes to present the 
antigens to T cells. The cognate T cells then proliferate and begin 
to remove the foreign antigens. The B cell-mediated immune 
response is mainly humoral, and occurs in peripheral lymphoid 
organs such as lymph nodes or the spleen. Thus, lymph nodes, 
Peyer’s patches, and the spleen act as a lymphocytic functional 
environment for both cellular and humoral immunity, and these 
lymphoid organs are referred to as secondary lymphoid organs 
(SLOs) or tissues, in contrast to the primary lymphoid organs 
(PLOs) – the thymus and bone marrow – where lymphocytes are 
produced and educated. These PLOs and SLOs develop during 
embryogenesis and early life. Postnatal lymphoid organs with 
a morphology similar to SLOs are induced to form in non-
lymphoid tissues such as those associated with chronic inflamma-
tion, chronic allograft rejection, or cancer, and these are known 
as tertiary lymphoid organs (TLOs) or structures (alternatively, 
ectopic lymphoid structures). TLOs are generally induced 
in areas of extensive local activation of cellular and humoral 
immune responses. TLOs are thought to play roles in immune 
responses that are similar to those of SLOs (22–26). One type 
of TLO, bronchus-associated lymphoid tissue (BALT), can inde-
pendently initiate local B- and T-cell responses (24) and serves 
as a reservoir of memory B and T cells (23). Mice with BALT are 
strikingly more resistant to pulmonary infection with a variety of 
infectious agents than mice without BALT (24, 26). Dieu-Nosjean 
et  al. have observed TLO components in lung cancers that are 
very similar (but not identical) to those of SLOs, being active in 
cellular and humoral immune responses (27, 28). In comparison 
to SLOs, TLOs are located very much closer to, or within, lesions 
and have similar immune function. Therefore, TLOs act as a front 
line base or bridgehead on the “immune battlefield.”
DeFiNiTiON, LOCATiON, AND 
STRUCTURe OF TLOs
Tertiary lymphoid organs can develop in various kinds of 
inflamed and non-lymphoid tissues including those associated 
with chronic infections, autoimmune diseases, chronic allograft 
rejection, and several solid cancers (29–34). TLOs are organized 
lymphoid structures similar to SLOs, characterized by B-cell 
follicles, T-cell zones, and specialized vessels known as high 
endothelial venules (HEVs), although TLOs are not encapsulated 
and supplied by afferent lymphatics.
Lymphocytic infiltration, lymphocyte trafficking, and 
lymphocyte homing are accurately regulated by several types 
of chemotactic factors and adhesion molecules expressed or 
demonstrated on endothelial cells or along the pathways of 
lymphocytic movement (35–37). The lymphocyte trafficking 
system allows appropriate subset of lymphocytes with appropri-
ate activity deploy to appropriate sites, areas, or tissues with 
appropriate timing. Effector or effector memory lymphocytes 
infiltrate into inflamed tissues, although large numbers of lym-
phocytes, particularly naive and central memory lymphocytes, 
accumulate in TLOs by homing through the HEVs from the 
blood by a multi-step mechanism that involves l-selectin-, 
chemokine-, and integrin-mediated lymphocyte-endothelial 
cell interaction (35, 36, 38). HEVs specifically express l-selectin 
ligands, including peripheral node addressin (PNAd), which are 
sulfated sialyl Lewis X molecules whose carbohydrate structures 
and biological function have been clarified by our group and 
others (37, 39–44). Chemokines CCL19 and CCL21 are necessary 
for the recruitment and disposition of T cells and DCs within 
lymphoid tissue, and chemokine CXCL13 functions in the 
recruitment and disposition of B cells. These chemokines are 
also involved in lymphoid neogenesis (29–34).
Location of TLOs in Cancer Tissues
Tumor-associated TLOs can be located peritumorally or intra-
tumorally (Figure  1). The majority of TLOs in cancer tissues 
develop in peritumoral areas, and are characterized as TLOs at 
the invasive front (or invasive margin), forming a wall around 
the cancer tissue. Peritumoral TLOs are positioned just outside 
the cancer tissue or in the periphery of the cancer (within the 
cancer-invasive area). Intratumoral TLOs are much rarer than 
peritumoral TLOs in common types of cancer, but the frequency 
of intratumoral TLOs varies depending on the tissue of cancer 
origin and the tumor type. If intratumoral TLOs are relatively 
abundant in a tumor type that usually shows only a low frequency 
of them, this suggests that the tumor is a limited or rather special-
ized case.
Structures of TLOs
Tertiary lymphoid organs have a structure similar to that of 
lymph nodes or Peyer’s patches. In addition to the histology, 
the constituent cells of TLOs and the molecules they express are 
quite similar to those in SLOs, as would be expected (46–48). 
T-zone T cells are CD62L+ and mainly central memory CD4+ 
T cells or naive T cells that accumulate via HEVs from the blood 
stream. The T cell area also contains immature and CD208+ 
mature DCs. The density of HEVs is strongly correlated with 
the density of CD3+ T cells, CD8+ T cells, CD20+ B cells, and 
CD208+ mature DCs (49). The B-cell follicle is composed of a 
mantle of naive B cells, surrounding a germinal center (GC) 
composed of highly proliferating B cells and a network of CD21+ 
follicular DCs. Development of the GC structure represents an 
active immune reaction, and the density of GCs in lung and breast 
cancers has been significantly correlated with patient outcome 
(48, 50, 51). In addition to lymphoid chemokines (CCL19, 
CCL21, CXCL13) and adhesion molecules (ICAM-2, ICAM-3, 
VCAM-1, MAdCAM-1), CCL17, CCL22, and IL16 are found in 
TLOs (48, 50–52). One interesting feature in lung cancer is that 
no NKp46+ NK cells are detected in TLOs (47), thus allowing 
FiGURe 1 | Histological features of TLOs (45) in chronic pancreatitis (A), igG4-related lymphoplasmacytic sclerosing pancreatitis (autoimmune 
pancreatitis) (B,C), and pancreatic ductal adenocarcinoma (PDAC) (D,e). TLOs are distributed evenly in inflamed tissues (A,B) and sometimes concentrated 
near the target structure (around ducts) (C). In contrast, cancer tissue is surrounded by peritumoral TLOs (D) and a rare pancreatic cancer case has intratumoral 
TLOs (D). Common PDAC has a paucity of vessels and lacks intratumoral TLOs, although limited cases do have intratumoral TLOs that are richer in tumor-infiltrating 
lymphocytes and retain relatively intact vascular networks consisting of arterioles, venules, and capillaries without cancer invasion.
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them to be distinguished from SLOs. NK cells and DCs are co-
localized in lymph nodes, and their interaction enhances NK cell 
proliferation, IFN-γ secretion, and cytotoxic function, as well as 
promoting DC maturation (47).
CLiNiCOPATHOLOGiCAL iMPACT OF 
TLOs iN HUMAN CANCeRS
The presence of TLOs in cancer tissues has been reported to be a 
favorable prognostic indicator (Table 1) (45, 48, 50–68), although 
some studies have concluded that this is not always the case (55, 
60), or may only apply to exceptional cancers such as renal cell 
carcinoma (61).
evaluation of TLOs
It is important to detect the presence of TLOs in both tumors 
and the tissues surrounding them. However, there is still no 
consensus regarding the best method for evaluation of TLOs as 
different approaches may be needed according to the types of 
cancer or the tissues from which they develop. Recent studies 
have detected TLOs using a combination of histological and 
immunohistochemical methods according to whether the 
TLOs have B-cell follicles, T-cell zones, and HEVs detected 
by immune-labeling for CD20+ cells, CD3+ cells, and PNAd+ 
vessels, respectively (Figure  2). This offers a basic approach 
that can evaluate the clinicopathological and biological char-
acteristics of TLOs from a neutral viewpoint. Other methods 
have adopted a morphological approach, or the use of specific 
markers such as lymphoid aggregates with CD208+ mature 
DCs, or the expression profiles of chemokine genes. These are 
good biomarkers for detection of TLOs with active immune 
reactions in lung, breast (48, 59), or colon cancers that are 
significantly correlated with a better patient outcome (57). One 
potential problem is that these markers are not always specific, 
for example the detection of CD208+ cells in cancer tissue as 
representative of the presence of TLOs can be applied to only 
limited types of cancer where all the CD208+ cells are mature 
DCs located within TLOs. Lung cancer is a good example of 
this, although in renal cell carcinoma CD208+ cells are present 
in non-TLO stroma (61).
Recently, the International TIL Working Group (2014) has 
informally recommended a method for evaluating TLOs in breast 
cancer within the existing method for evaluation of TILs (69). 
In breast cancer, it has been pointed out that TLOs are typically 
localized in the area surrounding the tumor, and may be localized 
in normal tissue directly adjacent to the tumor. However, only a 
limited population of breast cancers has apparent intratumoral 
TLOs. TILs are counted within the borders of the invasive tumor 
and exclude TLOs. Lee et  al. have evaluated TLOs using this 
recommended method and observed that TLOs were present 
mainly around carcinoma in situ (CIS) and in adjacent terminal 
duct lobular units (63, 64).
Frequency of TLOs
The frequency of TLOs varies, and tends to be dependent upon 
where the TLOs are located and the types of cancer (Table 1). 
At least one peritumoral TLO has been found in more than 
90% of cases of colorectal, pancreatic, and breast cancer, while 
intratumoral TLOs have been observed in only about 15% 
of colorectal and pancreatic cancers. About 20–40% of skin 
and oral mucosal cancers have TLOs, where the surfaces of 
background tissues are covered by squamous cell epithelium. 
TABLe 1 | Summary of TLOs in human cancers.
Cancer 
types
evaluation Numbers of case Location of 
TLOs
Frequency of TLOs 
(presence)
Prognostication Significant association Reference
Clinicopathological 
variables
TiL, TAM Others
Breast 
cancer
IHC (PNAd+ HEV) 146 (Stage I–III) Mixed 
(peritumoral and 
intratumoral)
ND Favorable (OS, DFS) No association (tumor size, 
grade, nodal metastasis, 
hormone receptor status, 
adjuvant chemotherapy, 
CD34+ blood vessel within 
cancer stroma)
CD3+T, CD8+T, 
FOXP3+ cells, ratio 
of FOXP3/CD3b, 
CD20+B
[Gene expression] 
related to Th1 cell 
orientation, cytotoxic 
granules, lymphoid 
chemokines, and T cell 
homing receptors
(48, 52)
Histology and 
IHC with gene 
expression (Tfh)
794 (Stage I–III, 
ER−HER2− 163, HER2+ 
120, ER+HER2− 510)
Mixed 
(peritumoral and 
intratumoral)
ND Favorable (DFS) in all 
patients, HER2+, or 
ER+HER2− patients 
ND Tfh, Th1 [Gene expression] 
CXCL13
(51)
Gene expression 
(Tfh, CXCL13)
996 [preoperative 
chemotherapy (+)]
Mixed 
(peritumoral and 
intratumoral)
ND Favorable ND ND ND (51)
Histology and IHC 
(CD3+T, CD20+B)
290 (Stage I–III, 
invasive carcinoma 
257, DCIS 33)
Peritumoral 110 (38.6%) No prognostic DCIS grade, ER statusb, 
PR statusb, HER2 status, 
tumor grade, nodal 
metastasis, histological TIL
ND ND (60)
Recommended 
histological 
criteria (68)
769 (Stage I–III, triple 
negative breast cancer)
Peritumoral 713 (92.7%: minimal 
17.2%, moderate 
36.2%, abundant 
39.4%)
Favorable (OSa, DFSa) Histological TIL ND ND (64)
Recommended 
histological 
criteria (68)
447 (Stage I to III, 
HER2+ invasive 
carcinoma)
Peritumoral 404 (79%: minimal 
37.1%, moderate 
31.3%, abundant 
10.2%)
No prognostic TIL, ER ALLred scoreb, 
HER2 IHC score, HER2 
copy number, DCIS 
percentage, HLA-A 
percentage, HLA-ABC 
percentage
ND ND (63)
Colorectal 
cancer
Gene expression 
(12 chemokines)
20 (Stage 0–IVA, 10 
the highest and 11 the 
lowest score tumors 
selected from 326)
Mixed 
(peritumoral and 
intratumoral)
ND Favorable (OS) No association (sex, tumor 
grade, tumor site, location, 
MSI-H/MSS status, tumor 
stage)
ND (Gene expression) 
related to cytotoxicity 
and DC 
(57)
Histology and IHC 418 (Stage I–IV) Peritumoral 
(extra-tumoral)
411 (98.3%) Favorable (OS) TNM stageb, preoperative 
radiotherapy or 
chemoradiotherapyb, 
deficient mismatch repair 
enzyme expression
CD3+T, CD8+T, 
FOXP3+, CD83+ 
(at invasive front 
and at stromal); 
CD3+T, CD8+T 
(intraepithelial)
(65)
149 (Stage I–IV) Peritumoral 
(extra-tumoral)
147 (98.7%) (65)
351 (Stage II 185, 
stage III 166)
Mixed 
(peritumoral and 
intratumoral)
276 (78.6%) Favorable (DFS) in 
stage II; no prognostic 
(DFS) in stage III
PNAd+HEV CD3+T (58)
IHC (PNAd+ HEV) 62 (Duke’s A and C) Peritumoral 
(extra-tumoral), 
intratumoral
Peritumoral TLO: 49 
(79%); intratumoral 
TLO: <8 (12.9%)
No prognostic More advanced disease, no 
association (MSI status)
ND (55)
(Continued)
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Cancer 
types
evaluation Numbers of case Location of 
TLOs
Frequency of TLOs 
(presence)
Prognostication Significant association Reference
Clinicopathological 
variables
TiL, TAM Others
Lung cancer IHC 
(CD208+mature DC)
74 (Stage I to II, ADC 
46, SCC 28)
Mixed 
(peritumoral and 
intratumoral)
ND Favorable (OS, 
DSS, DFS)
No association (sex, smoking 
history, histology, tumor 
grade, TNM stage, fibrosis, 
necrosis, Ki-67 tumor cells)
CD3+T, ratio of 
CD4/CD8, T-bet+, 
CD20+B
ND (46, 50, 59)
IHC (CD208+mature 
DC, follicular 
CD20+B)
122 (Stage III 
with neoadjuvant 
chemotherapy)
Mixed 
(peritumoral and 
intratumoral)
ND Favorable (DSS) ND ND An adaptive and 
specific humoral 
immune response (+)
(50)
IHC (CD208+mature 
DC)
458 (Stage I–IV, ADC 
241, SCC 111, others 
18, ND 6)
(Gene expression) 
related to cytotoxicity 
and Th1
(62)
Germ cell 
tumor
Histology 6 (Intracranial 
germinaom 2, 
seminoma 3, 
dysgerminoma 1)
Intratumoral TLO ND ND ND ND an adaptive and 
specific humoral 
immune response (+)
(66)
MALT 
lymphoma
Histology 20 (salivary gland) ND ND ND ND ND ND (53)
Skin 
Merkel cell 
carcinoma
Histology 21 (Stage I to IV) Mixed 
(peritumoral and 
intratumoral)
8 (38%) Favorable (DFS)a, no 
prognostic (OS)
No association (age, sex, 
TNM stage, extension status)
Ratio of CD8/
CD4 (at tumor 
periphery)
ND (54)
Oral 
squamous 
cell 
carcinoma
Histology and IHC 
(CD3+T, CD20+B, 
PNAd+HEV)
80 (Stage I to IV) Peritumoral 
predominant
17 (21%) Favorable (DSS)a No association (age, sex, 
smoking history, alcohol 
consumption, tumor site, 
tumor grade, TNM stage, 
treatment, HPV status)
ND ND (67)
Pancreatic 
cancer
Histology and IHC 
(CD3+T, CD20+B, 
PNAd+HEV)
308 (Stage I to IV) Intratumoral and 
peritumoral
Intratumoral TLO 49 
(12.9%), peritumoral 
TLO 308 (100%)
Only intratumoral TLO: 
favorable (OS, DFS)
Only intratumoral TLO: 
tumor gradeb, venous 
invasionb
Only intratumoral 
TLO: CD3+T, 
CD4+T, CD8+T, 
ratio of FOXP3/
CD4b, CD163+M2b
Only intratumoral 
TLO: (gene 
expression) related to 
Th1 and Th17
(45)
Histology and IHC 
(CD3+T, CD20+B, 
PNAd+HEV)
226 (Stage I to IV) Intratumoral and 
peritumoral
Intratumoral TLO 37 
(16.4%), peritumoral 
TLO 308 (100%)
Only intratumoral TLO: 
favorable (OS, DFS)
ND (45)
Renal cell 
carcinoma
IHC (CD208+mature 
DC)
135 (Clear cell RCC), 
51 ccRCC lung 
metastasis
Peritumoral? ND No prognostic 
(TLS-DC, OS, DFS), 
unfavorable (NTLS-DC, 
peritumoral, OS, DFS)
TLS-DC: PD-1+ cellsb, 
PD-L1, and/or PD-L2+ 
tumor cellsb
ND ND (61)
Cutaneous 
metastasis 
of malignant 
melanoma
Histology and IHC 
(CD3+T, CD20+B, 
PNAd+HEV)
29 Mixed 
(peritumoral and 
intratumoral)
7 (24% complete TLO), 
6 (20% incomplete TLO)
ND ND ND ND (56)
aBy only univariate analysis.
bNegatively associated.
ADC, adenocarcinoma; DCIS, ductal carcinoma in situ; DFS, disease-free survival; DSS, disease-specific survival; HPV, human papilloma virus; IHC, immunohistochemistry; MSI-H, microsatellite instability – high; MSS, microsatellite 
stable; ND, not determined; OS, overall survival; PNAd, peripheral node addressin; SCC, squamous cell carcinoma; TAMs, tumor-associated macrophages; TILs, tumor-infiltrating lymphocytes.
TABLe 1 | Continued
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FiGURe 2 | immunohistochemistry detecting a TLO having B-cell follicles, T-cell zones, and Hevs detected by immune-labeling for CD20+ cells, 
CD3+ cells, and PNAd+ vessels, respectively (45).
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TLOs in oral squamous cell carcinoma are found mainly in 
the peritumoral stroma within 0.5  mm from the tumor front, 
in lymphocyte-rich subepithelial areas (67). The density of 
TLOs in breast cancer shows a marked reduction from DCIS 
to invasive carcinoma, although other studies have obtained 
different findings (60).
Prognostic impact
The presence of TLOs is usually indicative of a favorable prog-
nosis, although a few reports have suggested it may have a rather 
negative prognostic impact (Table  1). Bento et  al. reported 
that the presence of extra-tumoral TLOs in colorectal cancer 
was significantly associated with more advanced disease (55). 
Figenschau et al. considered that cases of breast cancer associ-
ated with TLOs had a higher tumor grade and a high frequency 
of lymph nodal metastasis (60). These inconsistent results may 
explain why no universally accepted method for evaluating TLOs 
has emerged.
The location of TLOs has not been considered in the majority 
of previous studies. We have evaluated the clinicopathological 
impact of both peritumoral and intratumoral TLOs in two dif-
ferent cohorts of patients with pancreatic cancer (n = 308, 226). 
Though the presence and density of peritumoral TLOs were not 
prognostic, the presence of intratumoral TLOs was an independ-
ent prognostic factor. In only five cases (1.6%) that showed a 
higher density of intratumoral TLOs, four of the patients survived 
without recurrence at least 7 years after the surgery even though 
one of them had stage 2A disease, three were stage 2B, and one 
was stage 4 (45).
Association with Clinicopathologic 
variables
The presence of TLOs is basically independent of various clinico-
pathologic factors in several types of cancer (Table 1). Sometimes 
a few factors may be significantly associated with TLOs, although 
no definite tendency has yet emerged. The microsatellite instabil-
ity (MSI) subset of colorectal cancer has been shown to have an 
immunogenic character with massive TIL, although the rela-
tionship between TLOs and MSI is controversial; in colorectal 
cancers, two studies found no significant association (55, 57) 
and one study demonstrated a significant association whereby 
a more marked Crohn’s-like lymphoid reaction (extra-tumoral 
TLOs) was significantly associated with deficient expression of 
the mismatch repair enzyme (65).
Association with the immune 
Microenvironment
The presence and density of TLOs are significantly correlated with 
immune reaction in many cancers, although there are differences 
in degree among studies or cancer types (Table 1). TILs (TLOs are 
usually not counted as TILs) are better indicators of the immune 
microenvironment, as they lie within the tumor that are detected 
by histological examination, although it is impossible to avoid 
contamination from lymphocytes infiltrating into tissues sur-
rounding the cancer invasive area or lymphocytes in intratumoral 
TLOs in assays such as flow cytometry and RT-PCR using cells or 
tissues prepared on the basis of macroscopic findings.
Tertiary lymphoid organ presence and density are associated 
with mainly Th1- and cytotoxicity-related cellular immune reac-
tions that commonly occur in cancers of the breast, colorectum, 
lung, and pancreas (Table  1). TLO density is also associated 
with FOXP3+ cells but negatively associated with the FOXP3+/
CD3+T cell ratio or the FOXP3/CD4+T cell ratio, and also M2 
macrophages in breast and/or pancreatic cancer, being consistent 
with features mentioned above (45, 48). In the tumor microen-
vironment associated with TLOs, Th1- and cytotoxicity-related 
genes are commonly expressed, whereas DC-related genes are 
expressed in colorectal cancer and Th17-related genes in pancre-
atic cancer. Th2- and immune inhibition-related genes are not 
significantly associated with TLOs. The presence and density 
of TLOs are associated with CD20+ B cells. In breast and lung 
cancers, the size and density, or numbers, of B-cell follicles or 
GCs are significantly correlated with favorable outcome (50, 
51). Furthermore, in lung cancer and germ cell tumors, the 
presence of B-cell follicles in TLOs shows that the machinery 
for GC somatic hypermutation and class switch recombination 
is activated, along with the generation of plasma cells (50, 66). It 
has been thought that B cells play an important role in antitumor 
immunity, perhaps by capturing and presenting tumor antigens 
to T cells or by generating tumor antigen-specific antibodies that 
target tumor antigens to DCs expressing receptors for antibody 
constant regions. Germain et al. have stated that the presence of 
CD208+ mature DCs with a high density of B-cell follicles is a 
strong indicator of outcome in patients with lung cancers (50). 
Thus, it appears that a high density of TLOs is a good biomarker 
of a tumor immune microenvironment where active cellular and 
humoral immune reactions are occurring.
A recent study has also shown that Treg cells actively restrain 
effector T cells within tumor-associated TLOs. Localized Treg cell 
7Hiraoka et al. TLOs in Cancer Tissues
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depletion in a murine model of lung adenocarcinoma triggers 
robust effector T cell responses and tumor destruction, sug-
gesting that, in this model, Treg cells in TLOs actively restrain 
anti-tumor immunity (70). Therefore, in order to enhance the 
effects of immunotherapy, it is recommended that Treg depletion 
should be performed.
FORMATiON, MAiNTeNANCe, AND 
iNDUCTiON OF TLOs iN CANCeR 
TiSSUeS
Formation of SLOs and TLOs
The mechanism of SLO formation has been studied actively, and 
is considered to share a number of features with TLO formation. 
Details can be found in another review (29–34, 71). Molecular and 
cellular mechanisms exist for the development of SLOs (29–34, 
71). One pathway mainly for organogenesis of lymph nodes is 
initiated by interaction between CD3−CD4+CD45+ lymphoid 
tissue inducer (LTi) cells and stromal organizer (STo) cells at the 
lymph node anlagen. These specialized cells are of hematopoietic 
and mesenchymal lineage, respectively. Retinoic acid, probably 
derived from nerve fibers, induces the expression of CXCL13 in 
stromal cells. LTi cells accumulate in response to local expression 
of CXCL13 to form the first cell clusters. In response to IL-7 and 
TNFSF11, LTi cells are induced to secrete lymphotoxin (LT) α1β2. 
Interaction of LTα1β2 expressed on LTi cells with the LTβ receptor 
(LTβR) expressed on stromal cells allows the latter to differentiate 
into STo cells, resulting in secretion of the lymphoid chemokines 
CCL19, CCL21, and CXCL13 to recruit hematopoietic cells and 
increase the expression of VCAM-1, ICAM-1, and MAdCAM-1 
to ensure lymphocyte retention. Chemokines CCL19 and CCL21 
interact with their receptor CCR7 to recruit T cells and DCs, 
and chemokine CXCL13 interacts with the chemokine recep-
tor CXCR5 to recruit B cells. STo cells also secrete VEGF-C, 
FGF-2, and HGF, which promote development of the lymphatic 
vasculature and HEVs. STo cells also differentiate into stromal 
cell lineages including follicular DCs, fibroblastic reticular cells, 
and marginal reticular cells, which populate lymph nodes and 
contribute to SLO function. Another pathway operates mainly 
for Peyer’s patch formation. CD11c+ cells engage RET ligand 
expressed on gut, and RET-dependent signaling leads to expres-
sion of LTα1β2 by the CD11c+ cells. Interaction of these CD11c+ 
cells and LTβR+ stromal cells allows the latter to differentiate into 
STo cells, followed by steps similar to those responsible for forma-
tion of lymph nodes. It has been speculated that the mechanism 
responsible for formation of TLOs is similar to that for SLOs, 
especially lymph node and mucosal lymphoid tissues, since there 
are many features of TLOs that are common to the formation of 
SLOs. Th17, γδT cells expressing IL-17A, or innate lymphoid cell 
3 (ILC3) may substitute for LTi cells for development of TLOs (72, 
73). These cells share common features with LTi cells, e.g., pro-
duction of common cytokines such as IL-17A, IL-22, LTβ, TNF, 
and GM-CSF. T follicular helper (Tfh) cells expressing CXCL13 
are also implicated in the regulation of TLOs, representing a key 
initiator of lymphoid organogenesis that functions upstream of 
LTβR signaling, promoting B-cell activities, and supporting the 
generation of high-affinity antibodies at GCs (72, 74, 75). Instead 
of STo cells, stromal tissue cells such as synovial fibroblasts (e.g., in 
rheumatoid arthritis) contribute to TLO formation. CXCL13 can 
be produced by marginal reticular cells, Tfh and follicular DCs, 
as well as some monocytes/macrophages, a subset of memory 
T  cells, activated B cells, some endothelial cells, stromal cells, 
or epithelial cells in inflammatory foci. Chemokines, CXCL13, 
CCL19, CCL21, and CXCL12 are involved in not only the ini-
tiation of TLO development, but also maintenance of the highly 
organized cellular architecture of established SLOs and TLOs.
Formation and Maintenance of TLOs in 
Cancer Tissues
How do TLOs develop in human cancer tissues? Is the process 
different from that occurring in chronically inflamed tissue? 
Currently there is still no complete answer, although it likely 
involves (1) the state of antitumor immunity (tumor immuno-
genicity and immune microenvironment) and (2) the state of 
tissue structures necessary for formation/maintenance of TLOs.
A number of previous studies have indicated that an active 
immune response is usually present in background tissues with 
TLOs, both in cancer and chronic inflammation. The structures 
and contents of TLOs are comparable between these two situa-
tions, although cancer-associated TLOs show a high density of 
Tregs and absence of NK cells. The location of TLOs is another 
significant point, as mentioned above. In contrast to the evenly 
distributed TLOs in chronically inflamed tissues, TLOs in the 
majority of cancers are present in the area surrounding the 
invasive lesion, i.e., they are peritumoral TLOs. In non-invasive 
breast cancer (DCIS) (63, 64), it is interesting that non-invasive 
cancerous ducts or lobules, including peripheral ducts, are sur-
rounded by TLOs, bearing a histological resemblance to a chronic 
autoimmune reaction. In invasive cancers, almost the entire 
cancer tissue is surrounded by TLOs, and intratumoral TLOs 
are rarely present. Etiologically, TLO formation is expected to 
occur in tissues with active and continuous immune reactions 
involving active inflammation. This situation is common in 
tissues surrounding cancer, since the foreign antigens of cancer 
cells are presented continuously, tissue destruction caused by 
cancer invasion becomes a trigger of inflammation, and healthy 
non-cancerous tissue structures (blood vessels, nerve fibers, 
extracellular matrix, etc.) remain.
Arterioles and venules, which are small-sized arteries and 
veins, respectively, are associated with TLOs, and nerve fibers are 
usually found in TLOs in pancreatic cancers and chronic pancrea-
titis (45). TLOs, which develop in the pancreatic parenchyma in 
both chronic pancreatitis and pancreatic cancer, are always found 
in the interlobular spaces, where arterioles, venules, and relatively 
large nerve fibers are confined (45). It is speculated that these 
arterioles, venules, and nerve fibers are necessary for formation 
and/or maintenance of TLOs. The high frequency of arterial or 
venous invasion by cancer cells reduces the densities of arteries, 
arterioles, veins, and venules in the pancreatic cancer stroma. 
Common pancreatic cancers that have a high frequency of venous 
or arterial invasion lack intratumoral TLOs regardless of whether 
peritumoral TLOs are present. Conversely, intratumoral TLOs 
FiGURe 3 | Hypothesis of TLO formation/maintenance in cancer 
tissue, which likely involves (1) the state of antitumor immunity (tumor 
immunogenicity and host immune reaction) and (2) cancer 
invasiveness especially to vessels and tissue destruction that 
significantly affects the state of tissue structures necessary for 
formation/maintenance of TLOs. TLOs develop in the locations of venules 
in association with arterioles, venules, and nerve fibers (45). Cancer tissue 
that has become remodeled, showing absence of functional vascular 
networks replaced by abnormal blood vessels after invasion of cancer cells 
(center and left). Peritumoral TLOs can be induced if appropriate immune 
stimuli are present. Cancer tissue with intratumoral TLOs (right) shows a 
lower degree of cancer invasiveness, especially to vessels, and an active 
associated immune reaction. It retains relatively intact vascular networks, 
transporting immune cells, or other molecules into the cancer tissues, 
thereby rendering the antitumor immune reaction more effective. The scheme 
can apply to various solid cancers, although tendency of TLO development 
may be modified by tissue- and tumor type-specific properties.
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are found in pancreatic cancers with a low frequency of venous 
or arterial invasion (45).
A high frequency of venous invasion is found in TLOs at the 
invasive front. It is speculated that peritumoral TLOs in pancreatic 
cancer are destroyed and dispersed by cancer invasion, mainly 
venous invasion, and that other TLOs just outside the invasive 
front are induced to form. These in turn become surrounded by 
newly invasive cancer tissues, thus becoming new peritumoral 
TLOs, which are again subjected to invasion and destruction by 
further cancer invasion. These processes are repeated, resulting 
in cancer tissue being surrounded by peritumoral TLOs, whereas 
intratumoral TLOs are absent (Figure 3). Peritumoral TLOs can 
be induced if appropriate immune stimuli are present, since arte-
rioles, venules, and nerve fibers remain intact in the surrounding 
tissue outside the cancer-invasive area, being consistent with the 
above hypothesis.
It is noteworthy that pancreatic cancers with intratumoral 
TLOs show peculiar clinicopathological behavior, with a lower 
degree of cancer invasiveness, especially to venules, and an 
active associated immune reaction. In addition, the tumor 
microenvironment has abundant arterioles and venules without 
cancer invasion. Furthermore, there are relatively many blood 
vessels (mainly capillaries) that appear to be morphologically 
and immunohistochemically intact; there is higher expression 
of VE-cadherin, which is known to be abundant in quiescent 
and mature vessels (76, 77), and the density of endothelial 
cells in the abnormal blood vessels (so-called tumor vessels) 
is lower, lacking a covering of pericytes positive for α-smooth 
muscle actin (45). It is suggested that at least partly functional 
vascular networks are retained, transporting immune cells or 
other molecules into the cancer tissues, thereby rendering the 
antitumor immune reaction more effective, although vascular 
density is exceptionally low within the pancreatic cancer tis-
sue in general (78). Murine vascular studies have shown that 
vascular normalization in tumors enhances the influx of immune 
effector cells into the tumor parenchyma and markedly prolongs 
the survival of tumor-bearing mice (79, 80). Pancreatic cancers 
with intratumoral TLOs might offer a higher chance of effector 
immune cells, drugs, or effector molecules coming into contact 
with cancer cells as a result of immunotherapy, chemotherapy, 
or molecular targeting therapy.
Induction of TLOs after antitumor vaccination has been 
reported. Two weeks after vaccination with a granulocyte-
macrophage colony-stimulating factor (GM-CSF)-secreting 
pancreatic tumor vaccine (GVAX), intratumoral TLOs with an 
active cellular and humoral immune response were induced (81). 
However, it is not clear whether the postvaccination induced TLOs 
are identical to naturally occurring TLOs, since no comparison 
of the induced TLOs with naturally occurring TLOs is provided 
and HEV status is not mentioned in these induced TLOs (81). 
The induction of TLOs alone did not accurately predict the post-
vaccination patient outcome, since TLOs were induced in most 
vaccinated patients’ tumors (85%), although not all tumors from 
patients with short survival lacked induction of TLOs. Several of 
the 12 chemokines associated with TLOs in malignant melanoma 
and colorectal cancer (57, 82) expressed but downregulated in 
the induced TLOs in patients who have prolonged survival and 
elevated ratio of effector T cells to Tregs. Meanwhile, TLOs with 
an active immune reaction were reportedly induced in high-grade 
cervical intraepithelial neoplasias (CIN2/3) after intramuscular 
vaccination with HPV16 E6/E7 antigens (83). CIN2/3 can develop 
cervical squamous cell carcinoma, although no stromal invasion 
of cancer cells is found. Postvaccination TLOs were induced in 
the stroma subjacent to residual intraepithelial lesions. The first 
example is a TLO induced after the pancreatic cancer-associated 
remodeled tissue, while the second example shows TLOs develop 
in non-remodeled (but inflammatory) tissue next to the CIN. The 
second example is similar to the situation at the development 
of TLOs in persistent active chronic inflammation. It requires 
further study how TLOs are induced after vaccination more 
profoundly in the cancer-associated remodeled tissue. Although 
not all vaccination trials have been able to induce TLOs, these 
successes might provide clues to the molecular mechanisms 
occurring in developing TLOs, in addition to development of 
therapeutic interventions.
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Hev Formation and Maintenance
High endothelial venules are specially differentiated vessels 
that play important roles in the formation of lymphoid organs 
through accumulation of naive and central memory lymphocytes 
or other immune cells including DCs by providing an apparatus 
for extravasation of these cells from the blood stream into lym-
phoid organs (35–38). For this activity, HEVs specifically express 
and produce sulfated carbohydrate ligands, l-selectin ligands, 
and some adhesion molecules such as ICAM-1, VCAM-1, 
or MAdCAM-1 (36–44). HEV cells do not express lymphoid 
chemokines (CCL19, CCL21, and CXCL13) but present them 
at luminal surfaces through binding to scaffold molecules. Thus, 
HEVs are necessary for active and functional lymphoid organs.
Several studies have revealed that continuous engagement of 
LTβR on HEVs by LTα1β2+ cells is critical for the induction and 
maintenance of HEV gene expression and HEV cell morphology 
(84, 85). In mice, the major sources of LTα1β2 for HEV regula-
tion in lymphoid tissues are CD11c+ DCs and B cells (86–88). 
CD11c+ cells and activated B cells contribute to an increase of 
VEGF production, resulting in proliferation of endothelial cells in 
lymph nodes. Retention of routes for the recruitment of CD11c+ 
DCs into TLOs might be necessary in order to maintain the HEV 
phenotype in TLOs. It is assumed that if these routes are shut 
down by cancer invasion, HEV function will fail and the cellular 
content will be reduced, eventually leading to a decline in TLOs. 
Intratumoral HEVs would be expected to fail easily. In fact, in 
colorectal cancer, HEVs composed of flattened, atypical endothe-
lial cells without lymphoid aggregates are observed within the 
tumor, whereas HEVs composed of normal tall columnar to 
cuboidal-shaped endothelial cells with lymphoid aggregates are 
found in peritumoral areas (55).
CONCLUDiNG ReMARKS
Reports that have accumulated so far suggest that tumor- associated 
TLOs in many types of cancers play roles in the initiation and 
maintenance of active cellular and humoral immune responses 
against the cancers. Indeed, the presence of TLOs is significantly 
correlated with a favorable patient outcome and with a tumor 
immune microenvironment showing responses involving cellular 
and humoral immunity. The location of TLOs varies according to 
the type of cancer, and is important for evaluating the pathologi-
cal significance of TLOs, i.e., whether they develop as a response 
to the cancer or as a result of secondary inflammatory changes 
caused by cancer invasion. Although the developmental mecha-
nisms of TLOs are thought to be shared with those of SLO forma-
tion, we need to understand them in more detail, particularly the 
differences between TLOs that develop in non-cancerous tissues 
and those that develop in tissues remodeled by cancer invasion, 
and also the factors that trigger TLO development. In order to 
achieve this, we have to understand the real tumor-associated 
TLOs more and more with considering relationships of TLOs 
with cancer cells, and other stromal components including blood 
vessels, fibroblasts, and extracellular matrix. Unfortunately, any 
correlation between TLO formation and clinical outcome does 
not provide much information about the mechanism involved, 
and therefore both observational studies of human cancer and 
functional studies using reliable models will be required. It is 
anticipated that the presence (or higher density) of TLOs may be 
applicable as not only a prognostic marker but also a biomarker 
for selection of patients suitable for immunotherapy and/or for 
monitoring of patients during therapeutic intervention.
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